CompletedNot Applicable

Assays for and Reversal of New Anticoagulants

Australia30 participantsStarted 2012-04

Plain-language summary

New anticoagulants are being introduced to replace warfarin. These drugs do not require monitoring and are safer. There is currently no recommended way to reverse these drugs rapidly in the event of undue bleeding or need for emergency surgery. This is a lab study to look at ways to reverse the drugs rapidly

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Receiving dabigatran for atrial fibrillation * Or,for osteoarthritis of the hip or knee receiving rivaroxaban to prevent thromboembolic disease after total hip or knee replacement respectively Exclusion Criteria: * Failure to sign informed consent

What they're measuring

Ability to reverse anticoagulant effect in vitro of dabigatran or rivarovaban

Timeframe: Two hours after ingestion of anticoagulant dose

Trial details

NCT IDNCT01795781

SponsorR.P.Herrmann

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2013-04

View on ClinicalTrials.gov More Atrial Fibrillation trials